High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.

The QoLKAMON study evaluated quality of life, efficacy and treatment safety in HIV patients receiving lopinavir/ritonavir in monotherapy (MT) versus continuing combined antiretroviral triple treatment with a boosted protease inhibitor (TT).This was a 24-week, open-label, multicentre study in virolog...

Full description

Bibliographic Details
Main Authors: Juan Pasquau, Carmen Hidalgo-Tenorio, María Luisa Montes, Alberto Romero-Palacios, Jorge Vergas, Isabel Sanjoaquín, José Hernández-Quero, Koldo Aguirrebengoa, Francisco Orihuela, Arkaitz Imaz, María José Ríos-Villegas, Juan Flores, María Carmen Fariñas, Pilar Vázquez, María José Galindo, Isabel García-Mercé, Fernando Lozano, Ignacio de Los Santos, Samantha Elizabeth de Jesus, Coral García-Vallecillos, QoLKAMON STUDY GROUP
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5896909?pdf=render

Internet

http://europepmc.org/articles/PMC5896909?pdf=render

Similar Items